Benzinga | Jul 30, 2021 09:47AM EDT

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $190

Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and lowers the price target from $200 to $190.